Case Reports in Medicine

Volume 2012 (2012), Article ID 314056, 5 pages

doi:10.1155/2012/314056

Case Report

Hyperuricemic Renal Failure in Nonhematologic Solid Tumors: A Case Report and Review of the Literature

Neeraj Saini, Kyeong Pyo Lee, Smita Jha, Sanket Patel, Neelima Bonthu, Ankit Kansagra, Ashmeet Bhatia, Sandra E. Martinez, Jaymin Patel, Sarah Altamimi, and Sara Ghotb

Department of Internal Medicine, North Shore Medical Centre (NSMC), Salem, MA 01970, USA

Received 18 February 2012; Revised 27 March 2012; Accepted 29 March 2012

Academic Editor: Estella M. Matutes

Copyright © 2012 Neeraj Saini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Tumor lysis syndrome (TLS) is an oncologic emergency that is caused by massive tumor cell lysis. It is commonly associated with hematological cancers like leukemia and lymphoma and uncommonly with solid nonhematologic tumors as well. However, spontaneous tumor lysis syndrome (STLS) without any cytotoxic chemotherapy rarely occurs in solid tumors. We describe a case of STLS in a metastatic adenocarcinoma of unknown primary and review the literature of STLS in solid non-hematologic tumors to identify various risk factors for pathogenesis of this entity.

1. Case Report

A 59-year-old Caucasian female with past medical history of hypertension, obesity, mild osteopenia, and >20 pack years smoking history presented to the primary care physician with a more than four-month history of generalized weakness, anorexia, weight loss of more than 30 pounds, a growing subcutaneous mass in the right lower back and back pain in the lumbar region. MRI of the spine revealed confluent bulky soft tissue mass measuring approximately 14 cm anteroposterior × 13 cm transverse in size in the retroperitoneum region and pathological compression fracture of L1 vertebrae. Further, CT scan of chest/abdomen/pelvis confirmed bulky retroperitoneal mass/adenopathy with extensive liver metastases and multiple tiny pulmonary nodules (Figure 1).

Figure 1: Computed tomography of abdomen showing a big retroperitoneal mass engulfing the vascular structures in the abdomen.

The mass at lower back was excised and immunohistochemical staining of subcutaneous mass was positive for cytokeratin 7, cytokeratin 20, mucicarmine and villin but negative for ER, mammaglobin, TTF-1, napsin A, CDX2, p63, calretinin, and hepatocyte antigen. The villin positivity in conjunction with the cytokeratin 7 positive expression is suggestive of a noncolorectal gastrointestinal origin, including pancreaticobiliary/gallbladder source. The tissue of origin assay was unable to locate the primary source and subsequently, diagnosis of poorly differentiated adenocarcinoma of unknown primary was rendered. Ten days after the biopsy, while waiting for chemotherapy to begin, patient presented to her primary care physician with severe nausea and vomiting, altered mental status and decreased urine output. Basic metabolic panel (Chem-7) was consistent with dehydration with blood urea nitrogen (BUN) and creatinine of 31 mg/dL and 1.6 mg/dL, respectively, elevated from her baseline normal values about 10 days later. Patient was given a liter of intravenous fluid and was sent back home with antiemetics.

Four days later, after nausea and vomiting persisted with lethargy, weakness and very poor appetite, patient presented to emergency room. Chem-7 revealed BUN of 117 mg/dL with a creatinine of 7.5 mg/dL. Other pertinent lab values with normal values in parentheses showed calcium 6.5 (8.9–10.3) mg/dL, phosphorus 8.8 (2.6–4.6) mg/dL, uric acid 26.5 (2.8–6.6) mg/dL, and lactate dehydrogenase 1265 IU/L with normal transaminases. Obstructive uropathy was excluded by retroperitoneal ultrasound. Patient went into oliguric acute renal failure (ARF) and was treated with intravenous fluids. However, renal function did not improve over the next two days, and hemodialysis was started along with rasburicase. Lab abnormalities were consistent with TLS. Due to poor prognosis, patient was not started on chemotherapy and discharged to hospice without chemotherapy, and she died three weeks later.

2. Discussion

Tumor lysis syndrome (TLS) is an oncologic emergency that is caused by massive tumor cell lysis with the release of large amounts of potassium, phosphate, and nucleic acids into the systemic circulation. The Cairo-Bishop definition of TLS [1], proposed in 2004, provided both clinical and laboratory diagnostic and grading criteria for TLS as per below:

(i)laboratory TLS is defined as either a 25% change or level above or below normal for any two or more serum values of uric acid, potassium, phosphate, and calcium within 3 days before or 7 days after the initiation of chemotherapy in the setting of adequate hydration and without use of any uricosuric agent;(ii)clinical TLS is defined as laboratory TLS plus one or more of the following that was not directly attributed to a therapeutic agent: increased serum creatinine (≥1.5 times the upper limit of the normal, cardiac arrhythmia/sudden death, or a seizure);

TLS most often occurs after the initiation of cytotoxic therapy in patients with high-grade lymphomas (particularly the Burkitt subtype) and acute lymphoblastic leukemia. TLS has been rarely described after treatment of nonhematologic solid tumors including breast cancer, germ cell tumors [2], small-cell carcinoma (mostly involving the lung) [2, 3], medulloblastoma [2], sarcoma [2], metastatic colorectal cancer, gastrointestinal stromal tumors, melanoma [2], hepatocellular carcinoma [2], and other solid tumors as well. TLS has been shown to occur spontaneously without any cytotoxic therapy in hematologic cancers; however, it is very rare to find spontaneous tumor lysis syndrome (STLS) in solid tumors. The extensive search of Pubmed for STLS in non-hematologic solid tumors yielded 15 case reports including our case report (Table 1).

Table 1: Published Case reports of spontaneous tumor lysis syndrome in solid non-hematologic tumors published in the literature.

Age sex
Type of cancer
Primary site
Tumour burden and metastases
Lab values*
Treatment
Outcome

13, F [4]
Germ cell tumor–pure germinoma
Pineal and suprasellar mass
 cm pelvic mass with numerous peritoneal deposits
LDH
2310
Rasburicase with hydration Platinum-based chemotherapy given.
Survived

Uric acid
28

K; Ca; Ph
5.6; 7.2; 7.3

Creat
3.3

22, M [5]
Germ cell tumour–choriocarcinoma
Testis
Retroperitoneal mass of 14 cm in diameter with massive Liver and Lung metastases and numerous lymph nodes
LDH
4055
Hydration and rasburicase
Died

Uric acid
18

K; Ca; Ph
7.2; 9.6; 7.2

Creat
4.5

53, M [6]
Squamous cell Carcinoma
Maxillary Sinus
 cm papilloma in maxillary sinus with extensive metastases in liver
LDH
1000
Hydration; urinary alkalization with allopurinol and rasburicase
Died

Uric acid
20.9

K; Ca; Ph
7.6; 6.2; 11.8

Creat
6.4

74, M [7]
Squamous cell carcinoma
Lung
Stage 4
LDH
N/a
Hydration; uricolytic therapy with hemodialysis
Survived

Uric acid
15.4

K; Ca; Ph
5.2; n/a; 4.7

Creat
4.7

72, M [8]
Prostate carcinoma
Prostate
Extensive liver metastases and bone metastases
LDH
1288
Hydration; allopurinol, and daily hemodialysis
Died

Uric acid
28.1

K; Ca; Ph
4.9; 8.0; 8.3

Creat
6.1

82, F [9]
Colon carcinoma
Colon
Multiple large nonhomogenous liver masses with necrosis
LDH
2304
Hydration, alkalization, and allopurinol
Survived

Uric acid
20.4

K; Ca; Ph
n/a; 5.7; 5,5

Creat
3.5

80, M [9]
Pheochromocytoma
Adrenal glands
20 cm diameter mass on adrenal glands with central necrosis
LDH
964
Hydration, alkalization, and allopurinol
Survived

Uric acid
16.5

K; Ca; Ph
6.6; 8.4; 5.8

Creat
2.8

72, M [9]
Hepatocellular carcinoma
Liver
n/a
LDH
1024
Hydration, alkalization, and allopurinol
Died

Uric acid
20.1

K; Ca; Ph
4.5; 7.2; 5.4

Creat
3.2

52, M [10]
Germ cell tumor–endodermal Sinus tumor
n/a
Bulky para-aortic lymphadenopathy with liver and lung mets with necrotic tissue
LDH
13400
Hemodialysis and chemotherapy initiated
Survived but died 4 months later

Uric acid
21.8

K; Ca; Ph
7.9; 5.0; 7.1

Creat
4.19

24, M [10]
Germ cell tumor–seminoma
Testis
 cm retroperitoneal mass with liver metastases
LDH
13070
Hemodialysis with chemotherapy initiated. Later surgical removal of residual mass
Survived

Uric acid
24

K; Ca; Ph
8.5; 7.6; 10

Creat
5.06

50, M [11]
Metastatic adenocarcinoma of unknown primary
Unknown primary
Extensive tumor nodules in the liver with liver extending 17 cms below the costal margin with bulky lymphadenopathy and vertebral metastasis
LDH
n/a
Hydration with alkalization and allopurinol
Died

Uric acid
37

K; Ca; Ph
6.5; 8.3; 9.2

Creat
4.7

62, F [12]
Inflammatory breast cancer–lobular carcinoma
Breast
Large breast mass and supraclavicular lymphadenopathy with multiple mets in bones, lung, liver, and bone marrow
LDH
509
Allopurinol and chemotherapy initiated
Survived but died of recurrence 16 months later

Uric acid
10.1

K; Ca; Ph
n/a; 10.1; 6.0

Creat
0.9

36, M [13]
Gastric cancer adenocarcinoma
Stomach
Huge mass of more than 7 cm with multiple hepatic mets and lymphadenopathies
LDH
13924
Hydration, alkalization, allopurinol, hemodialysis, and chemotherapy initiated
Died

Uric acid
16.9

K; Ca; Ph
5.6; 7.0; 6.9

Creat
2.9

72, M [14]
Lung cancer adenocarcinoma
Lung
Large left upper lobe mass with multiple liver mets
LDH
1016
Hydration, potassium and phosphate binders, calcium gluconate, and allopurinol
Died

Uric acid
12.65

K; Ca; Ph
7.0; 8.2; 8.3

Creat
1.28

*Lab values are given as mg/dL for uric acid, serum creatinine, Potassium, Calcium and Phosphate and as IU/mL for LDH.

We believe that our case had STLS because of evidence of necrosis in the tumor and was probably precipitated by the dehydration aggravated due to nausea and vomiting. We excluded other causes for ARF, such as postrenal obstruction (by ultrasound and CT scan), urinary tract infection (urinalysis was normal for WBCs), parenchymal kidney disease (which does not develop so quickly and renal parenchyma appeared morphologically normal on ultrasound and CT scan). Elevated serum uric acid is present in acute renal failure of any cause, especially in prerenal azotemia, but values are generally below <15 mg/dL except in TLS. In our patient, serum uric acid >25 mg/dL was again consistent with TLS. The typical laboratory findings in outpatient such as hyperuricemia, hyperkalemia, hypocalcemia, hyperphosphatemia, and ARF met the laboratory and clinical criteria of TLS.

According to TLS expert panel guidelines [15], most solid tumors are classified as low risk for TLS, whereas tumors which are sensitive to chemotherapy or have high-proliferative index, such as neuroblastomas, germ cell, and small-cell lung cancers, are classified as intermediate risk. One-third of cases in Table 1 belonged to this intermediate risk group, notably germ cell tumors [4, 5, 10], coherent with the fact that highly proliferative tumors have more tendency to form large masses and presents with significant tumor burden offering them a more likelihood to induce STLS.

The risk factors for STLS in solid tumors, based on the review of literature and these case reports, include chemotherapy sensitive or high proliferative index tumors, tumor burden, presence of liver and bone metastasis, abnormal lab values including elevated serum uric acid, serum LDH, and concomitant presence of risk factors for renal failure. The most important risk factor was the tumor burden with every report documenting stage 4 cancers having extensive liver and bony metastases and presence of big-sized masses (>10 cm), which bestow them high predilection to undergo autonecrosis releasing intracellular contents. The biopsy in most of the cases revealed necrotic tissue in the center of the masses as well as in liver and bone metastases. The metastases in liver and bone compared to an abdominal mass are at higher risk to undergo ischemic central auto-necrosis due to pressure induced by surrounding normal parenchyma on a fast growing tumor, whereas, an intra-abdominal mass like in retroperitoneal region can grow to a significant size without lysis.

Another important risk factor would be preexistent impaired renal function that can be further compromised with the progression of the syndrome. The renal function deterioration can lead to deficient clearance of elevated uric acid produced by tumor lysis and deposition of the crystals in renal tubules (uric acid nephropathy). The use of nephrotoxic agents like intravenous contrasts agents, nonsteroidal anti-inflammatory drugs, nephrotoxic antibiotics and drugs that inhibit uric acid secretion (thiazides, and aspirin) should be avoided.

STLS is not as common in solid tumors compared to hematologic malignancies, but we believe that it might be an underdiagnosed entity, as many cases of mild grade TLS with less deranged abnormalities in the laboratory parameters can be missed easily. The patients with above risk factors should be treated prophylactically with aggressive hydration and uricolytic agents before the initiation of chemotherapy. Our case highlights the criticality of identifying STLS in solid tumors with big tumor burden and treating prophylactically to prevent this cataclysmic syndrome.

References

M. S. Cairo and M. Bishop, “Tumour lysis syndrome: new therapeutic strategies and classification,” British Journal of Haematology, vol. 127, no. 1, pp. 3–11, 2004.

L. Baeksgaard and J. B. Sørensen, “Acute tumor lysis syndrome in solid tumors—a case report and review of the literature,” Cancer Chemotherapy and Pharmacology, vol. 51, no. 3, pp. 187–192, 2003.

G. P. Kalemkerian, B. Darwish, and M. L. Varterasian, “Tumor lysis syndrome in small cell carcinoma and other solid tumors,” American Journal of Medicine, vol. 103, no. 5, pp. 363–367, 1997.

M. J. Murray, et al., “Intra-abdominal metastasis of an intracranial germinoma via ventriculo-peritoneal shunt in a 13-year-old female,” British Journal of Neurosurgery, vol. 25, pp. 747–749, 2011.

V. D'Alessandro, A. Greco, C. Clemente et al., “Severe spontaneous acute tumor lysis syndrome and hypoglycemia in patient with germ cell tumor,” Tumori, vol. 96, no. 6, pp. 1040–1043, 2010.

M. Abboud and A. Shamseddine, “Maxillary sinus squamous cell carcinoma presenting with fatal tumor lysis syndrome: a case report and review of the literature,” Case Reports in Oncology, vol. 2, pp. 229–233, 2009.

C. Shenoy, “Acute spontaneous tumor lysis syndrome in a patient with squamous cell carcinoma of the lung,” QJM, vol. 102, pp. 71–73, 2009.

C.-J. Lin, R. K. Hsieh, K. H. Lim, H. H. Chen, Y. C. Cheng, and C. J. Wu, “Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer,” Southern Medical Journal, vol. 100, no. 9, pp. 916–917, 2007.

E. Vaisban, A. Braester, O. Mosenzon, M. Kolin, and Y. Horn, “Spontaneous tumor lysis syndrome in solid tumors: really a rare condition?” American Journal of the Medical Sciences, vol. 325, no. 1, pp. 38–40, 2003.

G. Pentheroudakis, V. J. O’Neill, P. Vasey, and S. B. Kaye, “Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours. Report of two cases. Supportive care in cancer,” Official Journal of the Multinational Association of Supportive Care in Cancer, vol. 9, pp. 554–557, 2001.

D. R. Crittenden and G. L. Ackerman, “Hyperuricemic acute renal failure in disseminated carcinoma,” Archives of Internal Medicine, vol. 137, no. 1, pp. 97–99, 1977.

N. T. Sklarin and M. Markham, “Spontaneous recurrent tumor lysis syndrome in breast cancer,” American Journal of Clinical Oncology, vol. 18, no. 1, pp. 71–73, 1995.

I. S. Woo, J. S. Kim, M. J. Park et al., “Spontaneous acute tumor lysis syndrome with advanced gastric cancer,” Journal of Korean Medical Science, vol. 16, no. 1, pp. 115–118, 2001.

J. Feld, H. Mehta, and R. L. Burkes, “Acute spontaneous tumor lysis syndrome in adenocarcinoma of the lung: a case report,” American Journal of Clinical Oncology, vol. 23, no. 5, pp. 491–493, 2000.

M. S. Cairo, B. Coiffier, A. Reiter, and A. Younes, “Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus,” British Journal of Haematology, vol. 149, no. 4, pp. 578–586, 2010.